Canada · Delayed Price · Currency is CAD Vitalhub Earnings Call Transcripts
Fiscal Year 2026
-
Reported 47% year-over-year revenue growth and 11% organic ARR growth, with improved margins and strong cash position. Novari led growth, AI initiatives advanced, and board changes were made. Confident in double-digit ARR growth for 2026.
-
A healthcare IT vendor serving government-funded systems globally, the company drives growth through organic expansion and strategic acquisitions, with 80% recurring revenue and a strong cash position. AI integration and further M&A are expected to boost ARR and margins by 2026.
Fiscal Year 2025
-
Full year 2025 revenue surpassed CAD 100 million, with Q4 revenue up 52% year-over-year and strong ARR growth. Integration of recent acquisitions and AI initiatives are progressing, with further cost synergies and incremental ARR expected in 2026.
-
Q3 revenue nearly doubled year-over-year, driven by acquisitions and strong recurring revenue. Integration and cost reduction efforts are ongoing, with a focus on restoring EBITDA margins and leveraging AI for future growth.
-
Q2 2025 saw 55% ARR growth and a 47% revenue increase year-over-year, with strong cash reserves and a 26% adjusted EBITDA margin. Recent acquisitions are being integrated, with a focus on right-sizing and cross-selling, while maintaining double-digit ARR growth targets.
-
First quarter 2025 saw 54% ARR growth and 42% revenue growth year-over-year, with strong cash reserves and no debt. Integration of recent acquisitions is progressing, and the Induction deal is expected to close soon, supporting further M&A and product synergies.
-
A healthcare IT provider has grown to over $70 million ARR through 22 acquisitions and organic expansion, focusing on patient flow, engagement, and social care solutions outside the U.S. High recurring revenue, strong margins, and a cost-effective offshore R&D team support continued growth.
Fiscal Year 2024
-
Record Q4 revenue and ARR growth were driven by both organic expansion and four acquisitions, with strong performance across Canada, the U.K., and Australia. Adjusted EBITDA margin remained robust despite integration costs, and the company is well-capitalized to pursue further synergistic M&A in 2025.
-
Q3 2024 saw 25% revenue and ARR growth, driven by recurring software revenue and two major acquisitions. Pro forma ARR now stands at CAD 68 million, with strong cash reserves and a disciplined M&A strategy supporting future growth.
-
Q2 2024 saw 24% revenue growth and strong gains in recurring revenue, net income, and adjusted EBITDA, driven by organic expansion and acquisitions. The MedCurrent acquisition is set to close in September, with further M&A and process investments planned.